High-dose methotrexate
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First US approval record | Drugs@FDA earliest record for NDA 011719 (methotrexate injection, Hospira) is 10 Aug 1959, about 67 years | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA011719 (accessed 4 Nov 2026) |
| Mechanism | Blocks the enzyme dihydrofolate reductase, so cells cannot use folic acid to make DNA | NCI drug page https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate-sodium (accessed 31 Oct 2026) |
| Use in osteosarcoma | Part of MAP, first-line before and after surgery. UK: under 40. US label: adults and children with osteosarcoma as part of combination chemotherapy. UK SmPC (PL 11587/0052) lists osteosarcoma | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30eaef-5a09-4104-8a11-c32933eadeab; eMC https://www.medicines.org.uk/emc/product/8504/smpc; UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026) |
| Combined with | Doxorubicin and cisplatin (MAP); folinic acid (leucovorin) rescue; in France historically with etoposide and ifosfamide (M-EI) for young people | UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026); Macmillan (accessed 31 Oct 2026); treatment_by_country.md |
| Results | MIOS (1986, 36 randomised): 2-year relapse-free survival 66% with adjuvant chemotherapy (including high-dose methotrexate) against 17% with observation. EURAMOS-1 (2,260 registered, aged 40 or under, MAP): 5-year event-free survival 54%, 5-year overall survival 71% | MIOS, Link et al., NEJM 1986, doi:10.1056/NEJM198606193142502 (PMID 3520317), abstract accessed 4 Nov 2026; EURAMOS-1 full cohort, Smeland et al., Eur J Cancer 2019, doi:10.1016/j.ejca.2018.11.027 (PMID 30685685), abstract accessed 4 Nov 2026 |
| Side effects | Kidney damage that slows its own clearance; mouth sores; liver effects; low blood counts. Needs fluids, urine alkalinisation, blood level checks and folinic acid | Macmillan methotrexate (accessed 31 Oct 2026); DailyMed label above |
| Owner and generic status | Off patent; many makers (e.g. Hospira/Pfizer in US; medac and Pfizer in UK and Ireland) | Drugs@FDA NDA011719 (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/8504/smpc (accessed 4 Nov 2026) |
| Regulatory | UK: medac PL 11587/0052 (first 16 Nov 2007) lists osteosarcoma (adjuvant and neoadjuvant, in combination). EU (Ireland): Pfizer PA0822/206/007 lists osteosarcoma. US: osteosarcoma in label. China: domestic approvals e.g. Guangdong Lingnan H20054692. In CSCO MAP | eMC SmPC https://www.medicines.org.uk/emc/product/8504/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/22092/Licence_PA0822-206-007_11092026121412.pdf (accessed 4 Nov 2026); NMPA approval number H20054692 via yaopinnet.com mirror, https://www.yaopinnet.com/h/h92/H20054692.htm (accessed 4 Nov 2026); official NMPA register (datasearch.nmpa.gov.cn) returned HTTP 412 to automated access |
| Also worth noting | Glucarpidase (Voraxaze) is a bacterial enzyme approved in the US to reduce toxic methotrexate levels in adults and children whose kidneys clear it too slowly | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22glucarpidase%22 (accessed 4 Nov 2026) |
Hypotheses and open points (not established fact)
- Whether methotrexate adds benefit for people over 40 is debated; guidelines leave it out mainly because of toxicity (UK 2024 guideline; ESMO 2021 states preference for doxorubicin, cisplatin with or without ifosfamide over 40).